Full Press Release Details
Profusa Announces Third Quarter Business and
Financial Highlights
Recapitalization reduced net debt to $14 million
as of October 31; achieved key milestones to deliver potential 2026 revenue target
BERKELEY, Calif, November 19, 2025 (GLOBE NEWSWIRE)
- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company
pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces
financial results for the third quarter ended September 30, 2025, and provides business highlights.
Ben Hwang, Ph.D., Profusa's Chairman and
CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time.
In the third quarter, we achieved a significant milestone for the company with the completion of our merger with NorthView Acquisition
Corporation. We recapitalized our balance sheet, reducing net debt from $34 million to $14 million as of October 31, 2025. Since the
closing of the merger on July 11, 2025, we have raised $7 million in gross proceeds through our Equity Line of Credit ("ELOC")
transaction and an additional $2 million in convertible debt.
"We also delivered key operational milestones
including the build-out of our manufacturing capabilities; entered several potential distributor and clinical and commercial collaborations;
and built a team focused on executing the company's strategy.
"We now lead Profusa forward as we execute
on our plans to potentially achieve $200 to $250 million in revenue by 2030; capitalize on the near-term European and US Lumee oxygen
opportunity to deliver 2026 potential revenue of $0.5 to $2 million and $9 to $13 million potential revenue in 2027," concluded
Third Quarter 2025 Business Highlights:
Fred Knechtel, CFO of Profusa, commented, "To
deliver value to shareholders and provide the company with adequate capital to achieve near-term revenue goals and define long-term growth
strategies, we transformed the company's balance sheet by raising capital and reducing outstanding indebtedness. We intend to further
reduce debt to minimal levels in the next few quarters by exercising flexibility with debt to equity conversions, in addition to evaluating
opportunities with the capital markets as they arise."
Third Quarter 2025 Financial Highlights:
Based in Berkeley, Calif., Profusa is a commercial
stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors
in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data
for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa
aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
"LUMEE", "PROFUSA" and
the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this
"Press Release") may be considered "forward-looking statements" within the meaning of the "safe harbor"
provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future
events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology
such as "anticipate," "believe," "continue," "could," "estimate," "expect,"
"forecast," "future," "intend," "may," "might," "plan," "possible,"
"potential," "predict," "project," "propose," "seek," "should,"
"strive," "will," or "would" or the negatives of these terms or variations of them or similar terminology.
Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and
could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking
statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain.
Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future,
which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the
business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These
filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially
from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication
will prove to be accurate.
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924